CN106053835A - 川崎病的诊断标志物和治疗靶点 - Google Patents
川崎病的诊断标志物和治疗靶点 Download PDFInfo
- Publication number
- CN106053835A CN106053835A CN201610498798.6A CN201610498798A CN106053835A CN 106053835 A CN106053835 A CN 106053835A CN 201610498798 A CN201610498798 A CN 201610498798A CN 106053835 A CN106053835 A CN 106053835A
- Authority
- CN
- China
- Prior art keywords
- biomarker
- filamin
- level
- kit
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000011200 Kawasaki disease Diseases 0.000 title claims abstract description 211
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 title claims abstract description 211
- 230000001225 therapeutic effect Effects 0.000 title abstract description 11
- 239000000090 biomarker Substances 0.000 claims abstract description 138
- 102000013366 Filamin Human genes 0.000 claims abstract description 100
- 108060002900 Filamin Proteins 0.000 claims abstract description 100
- 108090000265 Meprin A Proteins 0.000 claims abstract description 80
- 108090000623 proteins and genes Proteins 0.000 claims description 98
- 102000004169 proteins and genes Human genes 0.000 claims description 98
- 239000012472 biological sample Substances 0.000 claims description 49
- 210000002700 urine Anatomy 0.000 claims description 44
- 239000000523 sample Substances 0.000 claims description 42
- 210000002966 serum Anatomy 0.000 claims description 42
- 239000003153 chemical reaction reagent Substances 0.000 claims description 31
- 238000003745 diagnosis Methods 0.000 claims description 27
- 238000010606 normalization Methods 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 6
- 108700039887 Essential Genes Proteins 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000008157 ELISA kit Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 37
- 108010026552 Proteome Proteins 0.000 abstract description 16
- 238000002560 therapeutic procedure Methods 0.000 abstract description 11
- 238000001514 detection method Methods 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 4
- 230000002485 urinary effect Effects 0.000 description 30
- 238000003556 assay Methods 0.000 description 23
- 238000002965 ELISA Methods 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 11
- 210000004351 coronary vessel Anatomy 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102100031262 Deleted in malignant brain tumors 1 protein Human genes 0.000 description 6
- 101000844721 Homo sapiens Deleted in malignant brain tumors 1 protein Proteins 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010003232 Arteritis coronary Diseases 0.000 description 5
- 108010074051 C-Reactive Protein Proteins 0.000 description 5
- 102100032752 C-reactive protein Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000003127 radioimmunoassay Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 108010074605 gamma-Globulins Proteins 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000004885 tandem mass spectrometry Methods 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 102100028281 ABC-type oligopeptide transporter ABCB9 Human genes 0.000 description 3
- 102100040807 CUB and sushi domain-containing protein 3 Human genes 0.000 description 3
- 101000892045 Homo sapiens CUB and sushi domain-containing protein 3 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 101000844719 Mus musculus Deleted in malignant brain tumors 1 protein Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 102000006463 Talin Human genes 0.000 description 3
- 108010083809 Talin Proteins 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 230000007310 pathophysiology Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 108010002947 Connectin Proteins 0.000 description 2
- 206010065420 Coronary artery dilatation Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101000724357 Homo sapiens ABC-type oligopeptide transporter ABCB9 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000009857 Microaneurysm Diseases 0.000 description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 208000004732 Systemic Vasculitis Diseases 0.000 description 2
- 102100026260 Titin Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001991 pathophysiological effect Effects 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 208000014001 urinary system disease Diseases 0.000 description 2
- 238000011265 2D-echocardiography Methods 0.000 description 1
- 101710192090 ABC-type oligopeptide transporter ABCB9 Proteins 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 238000010207 Bayesian analysis Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- -1 CAECAM Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000011799 Desmoglein Human genes 0.000 description 1
- 108050002238 Desmoglein Proteins 0.000 description 1
- 241000611421 Elia Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 1
- 101001050318 Homo sapiens Junctional adhesion molecule-like Proteins 0.000 description 1
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102100023437 Junctional adhesion molecule-like Human genes 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000214517 Lactobacillus casei group Species 0.000 description 1
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100030127 Obscurin Human genes 0.000 description 1
- 101710194880 Obscurin Proteins 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 102000008108 Osteoprotegerin Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010057517 Strep-avidin conjugated horseradish peroxidase Proteins 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000037881 acute idiopathic vasculitis Diseases 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000013477 bayesian statistics method Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000000738 capillary electrophoresis-mass spectrometry Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000011902 cervical lymphadenopathy Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008077 compensatory immune mechanism Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000006331 coronary aneurysm Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 229940124645 emergency medicine Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004784 molecular pathogenesis Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000008066 mucocutaneous inflammation Effects 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 238000005319 nano flow HPLC Methods 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000000101 novel biomarker Substances 0.000 description 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000008068 pathophysiological alteration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 208000030279 prolonged fever Diseases 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/328—Vasculitis, i.e. inflammation of blood vessels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161475936P | 2011-04-15 | 2011-04-15 | |
| US61/475,936 | 2011-04-15 | ||
| US201161579007P | 2011-12-22 | 2011-12-22 | |
| US61/579,007 | 2011-12-22 | ||
| CN201280024575.6A CN103562725B (zh) | 2011-04-15 | 2012-04-13 | 川崎病的诊断标志物和治疗靶点 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280024575.6A Division CN103562725B (zh) | 2011-04-15 | 2012-04-13 | 川崎病的诊断标志物和治疗靶点 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106053835A true CN106053835A (zh) | 2016-10-26 |
Family
ID=46208753
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610498798.6A Pending CN106053835A (zh) | 2011-04-15 | 2012-04-13 | 川崎病的诊断标志物和治疗靶点 |
| CN201280024575.6A Expired - Fee Related CN103562725B (zh) | 2011-04-15 | 2012-04-13 | 川崎病的诊断标志物和治疗靶点 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280024575.6A Expired - Fee Related CN103562725B (zh) | 2011-04-15 | 2012-04-13 | 川崎病的诊断标志物和治疗靶点 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9869673B2 (enExample) |
| EP (2) | EP2697653B1 (enExample) |
| JP (1) | JP6072768B2 (enExample) |
| KR (1) | KR20140034193A (enExample) |
| CN (2) | CN106053835A (enExample) |
| AU (1) | AU2012242684B2 (enExample) |
| CA (1) | CA2833257A1 (enExample) |
| WO (1) | WO2012142409A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI704349B (zh) * | 2019-06-17 | 2020-09-11 | 高雄榮民總醫院 | 蛋白質生物標記用以診斷川崎症的用途 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3137907A4 (en) * | 2014-05-02 | 2018-02-28 | Momenta Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of kawasaki disease |
| CN106796221B (zh) * | 2014-07-24 | 2019-12-17 | 陈垣崇 | 川崎氏症的诊断与治疗 |
| KR102056405B1 (ko) | 2018-04-05 | 2019-12-16 | (주)메디젠휴먼케어 | Ebf2 유전자 다형성을 이용한 가와사키병 발병 예측 방법 |
| CN110763845B (zh) * | 2018-07-27 | 2022-10-28 | 成都市第三人民医院 | 一种检测蛋白标志物的配体在制备用于诊断结肠癌的产品中的用途和试剂盒 |
| JPWO2022071601A1 (enExample) * | 2020-10-02 | 2022-04-07 | ||
| CN116087519B (zh) * | 2021-05-17 | 2025-03-14 | 郑州大学第一附属医院 | 一种用于高危人群贲门腺癌早期筛查的标志物及其应用 |
| KR102705469B1 (ko) * | 2022-05-30 | 2024-09-11 | 충남대학교산학협력단 | 불응성 가와사키병의 감별 진단을 위한 정보 제공 방법 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090093005A1 (en) * | 2007-10-05 | 2009-04-09 | University Of Virginia Patent Foundation | Protein-based biomarkers for abdominal aortic aneurysm |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
| US7429466B2 (en) | 2000-01-24 | 2008-09-30 | Hypromatrix, Inc | Methods and arrays for detecting biological molecules |
| US7112408B2 (en) | 2001-06-08 | 2006-09-26 | The Brigham And Women's Hospital, Inc. | Detection of ovarian cancer based upon alpha-haptoglobin levels |
| US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| US20030013208A1 (en) | 2001-07-13 | 2003-01-16 | Milagen, Inc. | Information enhanced antibody arrays |
| WO2007003594A1 (en) * | 2005-07-01 | 2007-01-11 | Solvay Pharmaceuticals Gmbh | Screening methods for inhibitors of the metalloprotease meprin |
| JP4795037B2 (ja) | 2006-02-01 | 2011-10-19 | 財団法人 神戸市地域医療振興財団 | 川崎病の判定方法及びそのためのキット |
| EP2180320A1 (en) * | 2006-06-05 | 2010-04-28 | Shimadzu Corporation | Tumor marker and method for determination of the occurence of cancerous disease |
| CA2660286A1 (en) * | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| EP2403877B1 (en) * | 2009-03-06 | 2015-05-06 | Klaus Tschira Stiftung GgmbH | Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient |
-
2012
- 2012-04-13 AU AU2012242684A patent/AU2012242684B2/en not_active Expired - Fee Related
- 2012-04-13 CA CA2833257A patent/CA2833257A1/en not_active Abandoned
- 2012-04-13 KR KR1020137030334A patent/KR20140034193A/ko not_active Withdrawn
- 2012-04-13 EP EP12725900.0A patent/EP2697653B1/en not_active Not-in-force
- 2012-04-13 CN CN201610498798.6A patent/CN106053835A/zh active Pending
- 2012-04-13 JP JP2014505335A patent/JP6072768B2/ja not_active Expired - Fee Related
- 2012-04-13 CN CN201280024575.6A patent/CN103562725B/zh not_active Expired - Fee Related
- 2012-04-13 US US14/111,816 patent/US9869673B2/en not_active Expired - Fee Related
- 2012-04-13 WO PCT/US2012/033514 patent/WO2012142409A2/en not_active Ceased
- 2012-04-13 EP EP16162648.6A patent/EP3086121A1/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090093005A1 (en) * | 2007-10-05 | 2009-04-09 | University Of Virginia Patent Foundation | Protein-based biomarkers for abdominal aortic aneurysm |
Non-Patent Citations (3)
| Title |
|---|
| KAZUNARI KANEKO，ET AL.: "Prediction of the Risk of Coronary Arterial Lesions in Kawasaki Disease by Brain Natriuretic Peptide", 《PEDIATR CARDIOL》 * |
| MING-YII HUANG，ET AL.: "Acute-Phase Reactants and a Supplemental Diagnostic Aid for Kawasaki Disease", 《PEDIATR CARDIOL.》 * |
| RYOTA EBATA，ET AL.: "Increased Production of Vascular Endothelial Growth Factor-D and Lymphangiogenesis in Acute Kawasaki Disease", 《CIRCULATION JOURNAL》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI704349B (zh) * | 2019-06-17 | 2020-09-11 | 高雄榮民總醫院 | 蛋白質生物標記用以診斷川崎症的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2697653A2 (en) | 2014-02-19 |
| AU2012242684A1 (en) | 2013-10-31 |
| KR20140034193A (ko) | 2014-03-19 |
| WO2012142409A3 (en) | 2013-02-28 |
| JP2014512014A (ja) | 2014-05-19 |
| US9869673B2 (en) | 2018-01-16 |
| CA2833257A1 (en) | 2012-10-18 |
| CN103562725A (zh) | 2014-02-05 |
| EP3086121A1 (en) | 2016-10-26 |
| US20140161791A1 (en) | 2014-06-12 |
| CN103562725B (zh) | 2016-08-17 |
| WO2012142409A2 (en) | 2012-10-18 |
| AU2012242684B2 (en) | 2017-04-20 |
| JP6072768B2 (ja) | 2017-02-01 |
| EP2697653B1 (en) | 2016-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103562725B (zh) | 川崎病的诊断标志物和治疗靶点 | |
| Richards et al. | Characterization and peripheral blood biomarker assessment of anti–Jo‐1 antibody–positive interstitial lung disease | |
| Kentsis et al. | Urine proteomics for discovery of improved diagnostic markers of Kawasaki disease | |
| CN105556308B (zh) | 用于阑尾炎的诊断和预后及腹痛病因的区分的方法和组合物 | |
| US11041867B2 (en) | ProADM and/or histones as markers indicating an adverse event | |
| CN109564225B (zh) | 作为指示不良事件的标志物的组蛋白和/或proADM | |
| US11719697B2 (en) | Immunoassay and antibodies for the detection of chromogranin A | |
| AU2017232081A1 (en) | Acute kidney injury | |
| Liu et al. | Methodological evaluation and comparison of five urinary albumin measurements | |
| Peñalver Penedo et al. | MR-Proadrenomedullin as biomarker of renal damage in urinary tract infection in children | |
| CN117242350A (zh) | 用于脓毒症的早期检测的il6标志物组 | |
| US8697368B2 (en) | Diagnostic marker for lung cancer comprising HPαR as active ingredient | |
| HK1193650A (en) | Diagnostic markers and therapeutic targets of kawasaki disease | |
| CN107076758B (zh) | 作为心力衰竭预后标志物的脑啡肽酶 | |
| JP7640168B2 (ja) | 夜尿症の患者の治療応答を予測する方法 | |
| Jiang et al. | Association and predictive value of immunoglobulin and complement levels for incident coronary heart disease: a nested case-control study in Chinese adults | |
| JP2014505256A (ja) | 急性冠動脈症候群後の心不全を検出し、予後を判定するためのガレクチン−３の使用 | |
| US20230305010A1 (en) | Timp1 as a marker for cholangiocarcinoma | |
| CN111323597A (zh) | 用于检测受试者中mci和/或ad的方法、试剂盒及筛选化合物的方法 | |
| EP4359800A1 (en) | Predicting cancer relapse | |
| WO2024014426A1 (ja) | 筋炎／皮膚筋炎に伴うリスクを検出する方法 | |
| US20200072847A1 (en) | System and methods for diagnosing acute interstitial nephritis | |
| CN117597584A (zh) | 用于脓毒症的早期检测的esm1标志物组合 | |
| Raziq et al. | Correlating Serum Biomarkers with Clinical Outcomes in Pediatric Sepsis; A Retrospective Observational Study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161026 |
|
| WD01 | Invention patent application deemed withdrawn after publication |